Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study.

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new ... she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO ... Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy, but investors are worried whether it ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NYSE:NVO ... brain fog she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave bed.

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from ... she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave ...

Novo Nordisk is under pressure from investors ... fatigue and brain fog she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can’t leave bed.

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO) is under pressure ... Novo stock slipped 1% before the bell on Tuesday. Novo believes CagriSema could be more powerful than its blockbuster ...